Figure S2. Survival Outcomes By Tumor PD-L1 Levels (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
| Autor: | Peter J. O'Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, Howard S. Hochster, Zev A. Wainberg |
|---|---|
| Rok vydání: | 2023 |
| DOI: | 10.1158/1078-0432.22475435.v1 |
| Popis: | Investigator-assessed PFS and OS in patients with PD-L1 expression cutoff of 1% (A, B) or 5% (C, D). HR, hazard ratio; mo, months; OS, overall survival; PD-L1, programmed cell death ligand-1; PFS, progression-free survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|